The Portnoy Law Firm has initiated an investigation into Immix Biopharma for possible securities fraud and may file a class action on behalf of investors. The inquiry focuses on whether the company or its leadership breached federal securities laws after media reports revealed that an executive using the alias Richard Graydon was allegedly Ronald Fischer, a top fugitive wanted in Rhode Island operating under an assumed identity. Immix disclosed that the officer was let go as of July 17, 2026, for reasons unrelated to his activities at the company, and due to his brief employment, management does not anticipate any material financial or operational impact. Following the reports, Immix's share price dropped by roughly 10.83%. Investors are encouraged to contact attorney Lesley F. Portnoy to discuss their legal rights.
Immix Biopharma IncInvestigation for possible securities fraud and executive's fugitive identity disclosure